Related Experiment Videos

Methicillin-resistant Staphylococcus aureus keratitis in the rabbit: therapy with ciprofloxacin, vancomycin and

M C Callegan1, J M Hill, M S Insler

  • 1Department of Microbiology, Louisiana State University Medical Center School of Medicine, New Orleans 70112.

Current Eye Research
|November 1, 1992
PubMed

Insights

Ciprofloxacin effectively treats methicillin-resistant Staphylococcus aureus (MRSA) eye infections in rabbits. Early topical application of ciprofloxacin demonstrated superior efficacy compared to vancomycin or cefazolin in clearing MRSA keratitis.

Area of Science:

  • Ophthalmology
  • Infectious Diseases
  • Pharmacology

Background:

  • Methicillin-resistant Staphylococcus aureus (MRSA) is a significant cause of bacterial keratitis.
  • Effective treatment options for MRSA keratitis are crucial to prevent vision loss.

Purpose of the Study:

  • To evaluate the efficacy of topical ciprofloxacin in treating experimental MRSA keratitis.
  • To compare ciprofloxacin's effectiveness against vancomycin and cefazolin.

Main Methods:

  • Experimental MRSA keratitis was induced in rabbit eyes via intrastromal injection.
  • Topical treatments (0.3% ciprofloxacin, 5.0% vancomycin, 5.0% cefazolin) were administered at different time points post-infection.
  • Bacterial load in corneas was quantified to assess treatment efficacy.

Main Results:

  • Early administration (4-9 hr postinfection) of ciprofloxacin eradicated MRSA in all treated eyes.
  • Ciprofloxacin showed significantly greater efficacy than vancomycin or cefazolin, even when treatment was initiated later (10-15 hr postinfection).
  • Bacterial killing was significantly higher with ciprofloxacin compared to vancomycin when treatment started at 10-20 hr postinfection.

Conclusions:

  • Topical ciprofloxacin is highly effective against MRSA keratitis in a rabbit model.
  • The efficacy of ciprofloxacin is time-dependent, with earlier application yielding better outcomes.
  • Ciprofloxacin represents a promising therapeutic option for MRSA-related eye infections.

Related Concept Videos